medcelerator · clinician one-pager
Ameluz Red-Light PDT Now FDA-Approved for Superficial Basal Cell Skin Cancer
Ameluz (aminolevulinic acid HCl 10% gel) — red-light PDT for superficial basal cell carcinoma
FDA Approved · United States · September 22, 2026
Condition: Superficial Basal Cell Carcinoma
Who this is for
This is for adults with superficial basal cell carcinoma — and the caregivers helping them — who may be candidates for labelled US Ameluz red-light PDT with a BF-RhodoLED or RhodoLED XL clinic lamp. It explains the 9 Sep 2026 sBCC expansion, Trial 4 clearance numbers, the two-session clinic regimen, photosensitivity and application-site pain honesty, how to ask a dermatologist for a PDT clinic that stocks the lamp, and why authorised is not funded — without treating Ameluz as home DIY gel, confusing this with the older AK-only story as the main pathway, or importing US tubes. Authorized is not funded.
Next clinical step
The US Food and Drug Administration (FDA) has approved this medicine. In the United States, ask your doctor or a specialist whether it suits you. They can write a prescription. Insurance or public drug plan coverage is not guaranteed.
Ways to access this treatment
United States · Prescription
US prescription (FDA-labelled)
https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/208081Orig1s040lbl.pdf
General resources for further research
ClinicalTrials.gov
US National Library of Medicine registry of clinical studies. Search by condition, drug, NCT number, and location. A listing is not enrolment, eligibility, or funding. Talk with the trial contact and a clinician before assuming a slot exists.
https://clinicaltrials.gov/
AI-produced discussion aid; not prescribing instructions. Approval does not establish coverage. Full article: https://medcelerator.com/articles/ameluz-aminolevulinic-acid-sbcc